Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Galera Therapeutics, Inc. (GRTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.27000.0000 (0.00%)
At close: 04:00PM EST
1.2600 -0.01 (-0.79%)
After hours: 07:43PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.2700
Open1.3000
Bid1.2400 x 2200
Ask1.2600 x 4000
Day's Range1.2100 - 1.3000
52 Week Range1.2050 - 12.9900
Volume833,845
Avg. Volume3,058,069
Market Cap32.073M
Beta (5Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-173.0880
Earnings DateMar 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.75
  • Zacks

    Coherus' (CHRS) Toripalimab Gets Orphan Drug Tag for Rare Cancer

    The FDA bestows an Orphan Drug designation to Coherus (CHRS) and partner Junshi's toripalimab for the treatment of esophageal cancer.

  • GlobeNewswire

    Galera to Present at Two Upcoming Investor Conferences in November

    MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences in November. Presentation Details: Event:Jefferies London Healthcare ConferenceDate:Nove

  • GlobeNewswire

    Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

    Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis Enrollment ongoing in GRECO-1 and GRECO-2 trials of rucosopasem (GC4711) in combination with SBRT in patients with NSCLC and pancreatic cancer; initial data from GRECO-1 expected in 1H 2022 Strong cash position of $89M with expected cash runway into 2023 MALVERN, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical c

Advertisement
Advertisement